Nevirapine

For research use only. Not for therapeutic Use.

  • CAT Number: A000432
  • CAS Number: 129618-40-2
  • Molecular Formula: C15H14N4O
  • Molecular Weight: 266.30
  • Purity: ≥95%
Inquiry Now

Nevirapine(Cat No.:A000432)is a high-purity non-nucleoside reverse transcriptase inhibitor (NNRTI) widely used in HIV research. It targets the HIV-1 reverse transcriptase enzyme by binding to an allosteric site, disrupting viral DNA synthesis and replication. Nevirapine is pivotal in studying antiretroviral therapy mechanisms, resistance patterns, and combination treatments. Known for its oral bioavailability and effectiveness, it is extensively used in exploring strategies to prevent mother-to-child HIV transmission. Its stability and efficacy make it a valuable tool for advancing HIV treatment research and developing innovative therapeutic approaches.


Catalog Number A000432
CAS Number 129618-40-2
Synonyms

129618-40-2; Viramune; BI-RG-587; Viramune XR; BIRG 0587

Molecular Formula C15H14N4O
Purity ≥95%
Target HIV
Solubility >13.3mg/mL in DMSO
Storage -20°C
IUPAC Name 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
InChI InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
InChIKey NQDJXKOVJZTUJA-UHFFFAOYSA-N
SMILES CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
Reference

1: Huang L, Carey V, Lindsey JC, Marzan F, Gingrich D, Graham B, Barlow-Mosha L,
Ssemambo PK, Kamthunzi P, Nachman S, Parikh S, Aweeka FT; IMPAACT P1079 protocol
team. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial
artemether-lumefantrine in African children. PLoS One. 2017 Oct
24;12(10):e0186589. doi: 10.1371/journal.pone.0186589. eCollection 2017. PubMed
PMID: 29065172; PubMed Central PMCID: PMC5655345.
<br>

2: Offor U, Ajayi SA, Jegede IA, Kharwa S, Naidu EC, Azu OO. Renal
histoarchitectural changes in nevirapine therapy: possible role of kolaviron and
vitamin C in an experimental animal model. Afr Health Sci. 2017
Mar;17(1):164-174. doi: 10.4314/ahs.v17i1.21. PubMed PMID: 29026390; PubMed
Central PMCID: PMC5636239.
<br>

3: Padmapriyadarsini C, Ramesh K, Sekar L, Ramachandran G, Reddy D, Narendran G,
Sekar S, Chandrasekar C, Anbarasu D, Wanke C, Swaminathan S. Factors affecting
high-density lipoprotein cholesterol in HIV-infected patients on nevirapine-based
antiretroviral therapy. Indian J Med Res. 2017 May;145(5):641-650. doi:
10.4103/ijmr.IJMR_1611_15. PubMed PMID: 28948955; PubMed Central PMCID:
PMC5644299.
<br>

4: Eloy P, Tessier A, Fan-Havard P, Chou M, Verstuyft C, Taburet AM, Haas DW,
Bertrand J; ANRS12154 Study Group. Genetics of nevirapine metabolic pathways at
steady state in HIV-infected Cambodians. Antimicrob Agents Chemother. 2017 Sep
25. pii: AAC.00733-17. doi: 10.1128/AAC.00733-17. [Epub ahead of print] PubMed
PMID: 28947469.
<br>

5: Paemanee A, Sornjai W, Kittisenachai S, Sirinonthanawech N, Roytrakul S,
Wongtrakul J, Smith DR. Nevirapine induced mitochondrial dysfunction in HepG2
cells. Sci Rep. 2017 Aug 23;7(1):9194. doi: 10.1038/s41598-017-09321-y. PubMed
PMID: 28835669; PubMed Central PMCID: PMC5569014.
<br>

6: Gopalan BP, Mehta K, D/’souza RR, Rajnala N, A K HK, Ramachandran G, Shet A.
Sub-therapeutic nevirapine concentration during antiretroviral treatment
initiation among children living with HIV: Implications for therapeutic drug
monitoring. PLoS One. 2017 Aug 21;12(8):e0183080. doi:
10.1371/journal.pone.0183080. eCollection 2017. PubMed PMID: 28827836; PubMed
Central PMCID: PMC5565187.
<br>

7: Pavlos R, McKinnon EJ, Ostrov DA, Peters B, Buus S, Koelle D, Chopra A,
Schutte R, Rive C, Redwood A, Restrepo S, Bracey A, Kaever T, Myers P, Speers E,
Malaker SA, Shabanowitz J, Jing Y, Gaudieri S, Hunt DF, Carrington M, Haas DW,
Mallal S, Phillips EJ. Shared peptide binding of HLA Class I and II alleles
associate with cutaneous nevirapine hypersensitivity and identify novel risk
alleles. Sci Rep. 2017 Aug 17;7(1):8653. doi: 10.1038/s41598-017-08876-0. PubMed
PMID: 28819312; PubMed Central PMCID: PMC5561238.
<br>

8: Moghadam NH, Salehzadeh S, Shahabadi N. Spectroscopic and molecular docking
studies on the interaction of antiviral drug nevirapine with calf thymus DNA.
Nucleosides Nucleotides Nucleic Acids. 2017 Sep 2;36(9):553-570. doi:
10.1080/15257770.2017.1346800. Epub 2017 Aug 8. PubMed PMID: 28786740.
<br>

9: Prasertvit P, Chareonyingwattana A, Wattanakrai P. Nevirapine patch testing in
Thai human immunodeficiency virus infected patients with nevirapine drug
hypersensitivity. Contact Dermatitis. 2017 Aug 6. doi: 10.1111/cod.12849. [Epub
ahead of print] PubMed PMID: 28782122.
<br>

10: Ciccacci C, Latini A, Politi C, Mancinelli S, Marazzi MC, Novelli G, Palombi
L, Borgiani P. Impact of glutathione transferases genes polymorphisms in
nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN
susceptibility. Eur J Clin Pharmacol. 2017 Jul 8. doi: 10.1007/s00228-017-2295-2.
[Epub ahead of print] PubMed PMID: 28689274.

Request a Quote